<DOC>
	<DOCNO>NCT00004896</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy donor bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness busulfan cyclophosphamide follow bone marrow transplantation treat patient acute myelogenous leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Busulfan Cyclophosphamide Followed Bone Marrow Transplantation Treating Patients With Acute Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine remission duration , disease-free survival , overall survival patient acute myelogenous leukemia remission early relapse myelodysplastic syndrome treat high-dose busulfan cyclophosphamide follow allogeneic bone marrow transplantation . OUTLINE : Patients receive oral high-dose busulfan every 6 hour 14-16 dos day -9 -6 , follow high-dose cyclophosphamide IV 1 hour day -5 -2 . Allogeneic bone marrow infuse day 0 . Patients already 1 transplant receive high-dose cyclophosphamide IV day -6 -5 , total body irradiation twice day day -4 -1 , allogeneic bone marrow infusion day 0 . All patient receive prophylaxis graft versus host disease . Patients follow every 6 month least 2 year . PROJECTED ACCRUAL : A total 25-40 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically proven ( bone marrow aspirate smear touch prep marrow biopsy ) acute myelogenous leukemia myelodysplastic syndrome 1 follow subtypes : Acute myeloblastic leukemia ( M1 , M2 ) Acute promyelocytic leukemia ( M3 ) Acute myelomonocytic leukemia ( M4 ) Acute monocytic leukemia ( M5 ) Acute erythroleukemia ( M6 ) Acute megakaryocytic leukemia ( M7 ) Refractory anemia Refractory anemia excess blast Refractory anemia excess blast transformation Refractory anemia ring sideroblast Chronic myelomonocytic leukemia In remission early relapse define less 20 % blast cell marrow overt active acute myeloid leukemia Suitable marrow donor , define sibling donor match HLAA , HLAB , HLAD/DR locus nonreactive bidirectional mixed lymphocyte culture donor mismatch 1 antigen locus Active CNS disease allow PATIENT CHARACTERISTICS : Age : 16 physiologic 60 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) unless due Gilbert 's disease SGOT great 3 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : Cardiac ejection fraction normal Pulmonary : FEV_1 least 50 % predict DLCO least 50 % predict Other : HIV negative No evidence persistent infection No concurrent organ damage medical problem would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>